Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$1.71
▼ $0.19 (-10.0%)
Market data updated: 09/20 04:12 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$55.26M
Day Range
$1.65 - $1.90
52-Week Range
$1.07 - $71.50
Beta
—
Next Earnings
11.11.2026
Support
$1.07
Resistance
$4.27
BCAB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-94.8% (1Y)
Strengths: 9/25 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 29.9%
Growth
Biggest negative driver
Operating margin
Operating margin: -2985.5% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
46
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $1.71
Evidence: Narrative Gap moved from -5 to 26 day-over-day
What happened after
Still awaiting outcome
today · $1.71
Evidence: FOMO score jumped from 8 to 38 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
63
Quality
63
Value
55
Momentum
30
Risk
32
Sentiment
80
Fundamental
25
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **BioAtla, Inc.** has focused solely on its **imminent delisting from Nasdaq**, with a SEC filing confirming the company will be removed from the exchange on **August 31, 2026**, transitioning to over-the-counter (OTC) trading. No other substantive updates or developments about BioAtla’s operations, research, or financials were reported in the provided sources. The headlines primarily highlight broader healthcare stock movements without specific mention of BioAtla beyond this regulatory action.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about BioAtla, Inc.. News trend score: 80. Reason: 5 of the last 6 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
41
🎯 Conviction (vs. Emotion)
54
Psychology
100
Fundamentals
25
Technical
30
Valuation
55
The price rise has far outpaced the actual improvement in fundamental data.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-51%
Market Narrative
80
Fundamental Reality
54
Narrative Gap
+26
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The market’s extreme loss aversion (score 100) reflects a deep price drawdown (-60.4% over three months) and subdued trading activity, consistent with investors clinging to positions to avoid realized losses. Panic selling (score 55) is also present, evidenced by elevated volatility and extreme oversold conditions (RSI 20), but not yet dominant. The key open question is whether the current low volume and lack of follow-through momentum will persist or if a rebound could emerge as profit-taking stabilizes. The narrative gap (-5) suggests a slight disconnect between market sentiment and fundamentals, but the dominant psychological state remains anchored in loss aversion.
Updated: 09/08/2026, 01:56 AM
What could change this?
🧠 Market Brain events driving this
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 92/100
🔴 Weakest match
Walter Bagehot — 31/100
🗣️ Why do they disagree?
Based on the documented principles of each investor, the model estimates that cycle‑aware thinkers such as Howard Marks (market‑cycle) and crowd‑sentiment observers like Charles Mackay and Thorstein Veblen assign modestly positive scores (79, 73, 67) because they perceive the stock as early‑to‑mid‑cycle and aligned with real value creation. In contrast, investors who require concrete growth, dividend, or balance‑sheet data—Peter Lynch, Philip Fisher, Benjamin Graham and others—issue neutral or “not enough data” verdicts despite Lynch’s perfect raw score, reflecting their reliance on detailed fundamentals that are absent. Risk‑oriented and trend‑following approaches, exemplified by Gerald Loeb, Jesse Livermore, and the efficient‑market advocates, deliver low scores (13‑44) and caution that the stock’s risk profile or lack of a clear trend makes it unattractive. Overall, the divergence stems from each methodology’s core filter: cycle and sentiment lenses see modest potential, while data‑driven, risk‑focused, or index‑favoring frameworks view the investment as insufficiently substantiated.
Peter Lynch
One Up on Wall Street (1989)
🟢 92
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 80
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 70
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 65
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 64
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 61
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 56
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 48
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 47
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 46
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 46
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 33
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 31
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 7 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-2985.5%
Net Margin
-2980.3%
EBITDA Margin
—
ROE
-489.1%
ROA
-431.1%
ROIC
—
EPS
-$1.01
Cash
$7.12M
Total Debt
—
Current Ratio
0.37
Debt/Equity
0.00
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$12.28
Tangible Book Value per Share (Tangible NAV)
$3.79
Sentiment based on basic keywords (not AI) — 5 positive, 1 neutral, 0 negative out of the last 6 articles.
Benzinga · 28.8.2026
Benzinga · 28.8.2026
Benzinga · 28.8.2026
Benzinga · 27.8.2026
Benzinga · 21.8.2026
Benzinga · 11.8.2026
BioAtla, Inc. (BCAB) currently has a StockIQ AI score of 46/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
BCAB currently scores 46/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
BCAB's technical score is 30/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 29.9%; Operating margin is stable or improving over time; Debt/equity: 0.00.
Based on the real signals StockIQ computed: Operating margin: -2985.5% (negative); Net margin: -2980.3% (negative); ATR: 25.2% of price.
StockIQ has no recorded dividend payment history for BCAB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Sievers Eric | Tax Withholding in Shares | 31.8.2026 | 134 | -134 | $1.69 |
| SHORT JAY M PHD | Tax Withholding in Shares | 31.8.2026 | 259 | -259 | $1.69 |
| Vasquez Christian | Tax Withholding in Shares | 31.8.2026 | 71 | -71 | $1.69 |
| SHORT JAY M PHD | Tax Withholding in Shares | 31.5.2026 | 259 | -259 | $3.93 |
| Sievers Eric | Tax Withholding in Shares | 31.5.2026 | 134 | -134 | $3.93 |
| Vasquez Christian | Tax Withholding in Shares | 31.5.2026 | 82 | -82 | $3.93 |
| SHORT JAY M PHD | Tax Withholding in Shares | 31.5.2026 | 52,294 | -259 | $3.93 |
| Sievers Eric | Tax Withholding in Shares | 31.5.2026 | 11,840 | -134 | $3.93 |
| Vasquez Christian | Tax Withholding in Shares | 31.5.2026 | 10,347 | -82 | $3.93 |
| SHORT JAY M PHD | Tax Withholding in Shares | 12.3.2026 | 639 | -639 | $0.17 |
| SHORT JAY M PHD | Tax Withholding in Shares | 12.3.2026 | 52,553 | -639 | $0.17 |
| Sievers Eric | Tax Withholding in Shares | 11.3.2026 | 360 | -360 | $0.17 |
| Vasquez Christian | Tax Withholding in Shares | 11.3.2026 | 175 | -175 | $0.17 |
| SHORT JAY M PHD | Grant/Award from Employer | 11.3.2026 | 430,000 | +430,000 | — |
| SHORT JAY M PHD | Grant/Award from Employer | 11.3.2026 | 2,659,603 | +430,000 | — |
| Sievers Eric | Tax Withholding in Shares | 11.3.2026 | 11,614 | -360 | $0.17 |
| Vasquez Christian | Tax Withholding in Shares | 11.3.2026 | 10,429 | -175 | $0.17 |
| Vasquez Christian | Grant/Award from Employer | 10.3.2026 | 240,000 | +240,000 | — |
| Sievers Eric | Grant/Award from Employer | 10.3.2026 | 240,000 | +240,000 | — |
| Vasquez Christian | Grant/Award from Employer | 10.3.2026 | 530,196 | +240,000 | — |
| Sievers Eric | Grant/Award from Employer | 10.3.2026 | 598,705 | +240,000 | — |
| SHORT JAY M PHD | Tax Withholding in Shares | 28.2.2026 | 7,728 | -7,728 | $0.25 |
| Vasquez Christian | Tax Withholding in Shares | 28.2.2026 | 1,802 | -1,802 | $0.25 |
| WALDRON RICHARD A | Tax Withholding in Shares | 28.2.2026 | 2,729 | -2,729 | $0.25 |
| Sievers Eric | Tax Withholding in Shares | 28.2.2026 | 3,140 | -3,140 | $0.25 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
204,122 shares short as of 2026-08-31 · vs. 105,433 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
47.5% of trading volume this week was short selling, vs. 45.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology